Forte Biosciences Inc
FBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.58B
Close$
$5.23
93.2% downside
Current Fair Value
93.2% downsideOvervalued by 93.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.71 |
| Beta | 2.65 |
| Outstanding Shares | 23,787,713 |
Return
| Return on Equity | -47.85% |
|---|---|
| Return on Assets | -42.74% |
| Return on Invested Capital | -48.13% |
Valuation & Multiples
| P/E Ratio | -16.76 |
|---|---|
| PEG | -15.6 |
| Price to Sales | - |
| Price to Book Ratio | 10.98 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -17.1 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5158▲ 51.58% |
|---|---|
| Total Calls | 44,400▲ 98.21% |
| Total Puts | 22,900▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.19%▲ 1.36% |
|---|---|
| Total Invested | $350.24M▲ 11.36% |
| Investors Holding | 71▲ 11.00% |
ESG Score
No data
About Forte Biosciences Inc
9 employees
CEO: Martin Duvall Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age an...